SeQuent Scientific Limited (SeQuent) today announced EUGMP approval of its dosage tablet manufacturing line in Turkey. The approval was completed with the successful renewal of the EUGMP license for 8 more manufacturing lines for various dosage forms including beta-lactam, non-beta-lactam, terminal sterilization, mastitis, beta-lactam powder, aerosol, pesticide and strong in Turkey. In addition to EUGMP, manufacturing lines in Turkey also hold GMP certificates from Turkish, Saudi, Ethiopian and Sudanese authorities. With these approvals, Alivira now has several EUGMP approved facilities around the world, allowing it to better meet the needs of its customers in regulated markets in Europe and access alternative manufacturing sites to ensure the supply of high quality products.
With more than 120 product registrations, SeQuent is the third player in the Turkish ruminant market with a consolidated market share of around 10%, operating through its 100% subsidiaries of Provet and Topkim. The company has already embarked on a significant expansion in Turkey to meet the growing demands of the local market while leveraging locations for European and other strategic markets.
Shares of SEQUENT SCIENTIFIC LTD. Last traded on BSE at Rs.269.25 from the previous close of Rs. 269.25. The total number of shares traded during the day was 91,250 in more than 3,025 transactions.
The share hit an intraday high of Rs. 273 and an intraday low of 266.5. The net turnover during the day was Rs. 24,583,044.